Prescription of guideline-directed medical therapies in patients with diabetes and chronic kidney disease from the CURE-CKD Registry, 2019-2020
| Autor: | Nicholas, Susanne B, Daratha, Kenn B, Alicic, Radica Z, Jones, Cami R, Kornowske, Lindsey M, Neumiller, Joshua J, Fatoba, Samuel T, Kong, Sheldon X, Singh, Rakesh, Norris, Keith C, Tuttle, Katherine R |
|---|---|
| Rok vydání: | 2023 |
| Předmět: |
Kidney Disease
diabetic nephropathy Diabetes Clinical Sciences Renal and urogenital Evaluation of treatments and therapeutic interventions Endocrinology & Metabolism Good Health and Well Being elecronic health records data Clinical Research 6.1 Pharmaceuticals type 2 diabetes kidney and cardiovascular protective drugs real-world evidence Metabolic and endocrine |
| Popis: | AimGuideline-directed medical therapy (GDMT) is designed to improve clinical outcomes. The study aim was to assess GDMT prescribing rates and prescribing-persistence predictors in patients with diabetes and chronic kidney disease (CKD) from the Center for Kidney Disease Research, Education, and Hope Registry.Materials and methodsData were obtained from adults ≥18 years old with diabetes and CKD between 1 January 2019 and 31 December 2020 (N = 39 158). Baseline and persistent (≥90 days) prescriptions for GDMT, including angiotensin converting enzyme (ACE) inhibitor/angiotensin receptor blocker (ARB), sodium-glucose cotransporter-2 (SGLT2) inhibitor and glucagon-like peptide 1 (GLP-1) receptor agonist were assessed.ResultsThe population age (mean ± SD) was 70 ± 14 years, and 49.6% (n = 19 415) were women. Baseline estimated glomerular filtration rate (2021 CKD-Epidemiology Collaboration creatinine equation) was 57.5 ± 23.0 ml/min/1.73 m2 and urine albumin/creatinine 57.5 mg/g (31.7-158.2; median, interquartile range). Baseline and ≥90-day persistent prescribing rates, respectively, were 70.7% and 40.4% for ACE inhibitor/ARB, 6.0% and 5.0% for SGLT2 inhibitors, and 6.8% and 6.3% for GLP-1 receptor agonist (all p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|